Table 1. Demographic and Clinical Characteristics by Neuropathological Diagnosis.
| Characteristic | No. (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total (N = 1808)a | AD (n = 1246) | LBD (n = 658) | CAA (n = 1117) | CVD (n = 568) | FTLD (n = 303) | HS (n = 254) | NP (n = 131) | |
| Age at death, mean (SD), y | 80.0 (11.0) | 80.8 (10.4) | 79.6 (9.9) | 80.6 (10.6) | 84.4 (9.4) | 77.5 (11.3) | 82.3 (10.0) | 76.2 (13.3) |
| Age at last visit, mean (SD), y | 78.7 (11.2) | 79.4 (10.7) | 78.1 (10.2) | 79.2 (10.9) | 82.9 (9.7) | 76.2 (11.5) | 80.8 (10.3) | 75.2 (13.3) |
| Female | 821 (45.4) | 602 (48.3) | 277 (42.1) | 523 (46.8) | 282 (49.6) | 126 (41.6) | 128 (50.4) | 42 (32.1) |
| Male | 987 (54.6) | 644 (51.7) | 381 (57.9) | 594 (53.2) | 286 (50.4) | 177 (58.4) | 126 (49.6) | 89 (67.9) |
| Education, mean (SD), y | 15.51 (3.11) | 15.42 (3.16) | 15.70 (3.05) | 15.44 (3.19) | 15.37 (3.14) | 15.87 (2.99) | 15.60 (3.22) | 15.84 (2.99) |
| Whiteb | 1710 (94.6) | 1177 (94.5) | 627 (95.3) | 1051 (94.1) | 539 (94.9) | 290 (95.7) | 238 (93.7) | 126 (96.2) |
| Total NPIQ score, mean (SD)c | 5.41 (4.49) | 5.37 (4.36) | 5.67 (4.41) | 5.30 (4.35) | 4.85 (4.25) | 6.08 (4.57) | 5.36 (3.95) | 6.22 (5.69) |
| APOE ε4 positive | 707 (44.9) | 606 (55.4) | 310 (53.4) | 556 (56.7) | 207 (42.1) | 76 (28.4) | 110 (49.8) | 20 (18.5) |
| ChEI or memantine use | 1114 (61.6) | 886 (71.1) | 475 (72.2) | 774 (69.3) | 325 (57.2) | 142 (46.9) | 194 (76.4) | 42 (32.1) |
| Antipsychotic use | 391 (21.6) | 302 (24.2) | 165 (25.1) | 249 (22.3) | 104 (18.3) | 55 (18.2) | 50 (19.7) | 23 (17.6) |
| Anxiolytic or sedative use | 523 (28.9) | 345 (27.7) | 193 (29.3) | 310 (27.8) | 145 (25.5) | 88 (29.0) | 62 (24.4) | 43 (32.8) |
| Antidepressant use | 983 (54.4) | 700 (56.2) | 381 (57.9) | 616 (55.1) | 268 (47.2) | 156 (51.5) | 146 (57.5) | 73 (55.7) |
| Time from final visit to death, mean (SD), y | 1.79 (1.92) | 1.87 (2.00) | 1.97 (2.03) | 1.91 (1.98) | 1.95 (2.03) | 1.82 (1.87) | 2.02 (2.02) | 1.51 (1.65) |
Abbreviations: AD, Alzheimer disease (defined by intermediate or high ABC criteria); APOE, apolipoprotein E; CAA, cerebral amyloid angiopathy; ChEI, cholinesterase inhibitor; CVD, cerebrovascular disease; FTLD, frontotemporal lobar degeneration; HS, hippocampal sclerosis; LBD, Lewy body disease; NP, no known pathology; NPIQ, Neuropsychiatric Inventory Questionnaire.
Number of participants in each category does not add up to the total because some participants had more than 1 neuropathology diagnosis.
Race and ethnicity data were collected via self-report as per National Alzheimer Coordinating Center protocol. Categories other than White are not reported because of low numbers.
NPIQ mean total score across assessment time points. Medication use at any time point was rated.